Venetoclax在复发/难治性多发性骨髓瘤中的研究进展  

Research Progress of Venetoclax in Relapsed/Refractory Multiple Myeloma

作　　者：费林荣 王俊慧 卢传洋 陈月[1,2] 马晶晶[1,2] 于亮[1,2] FEI Linrong;WANG Junhui;LU Chuanyang;CHEN Yue;MA Jingjing;YU Liang(Department of Hematology,Huai′an First People′s Hospital Affiliated to Nanjing Medical University,Huai′an 223300,China;Key Laboratory of Hematology of Nanjing Medical University,Nanjing 210009,China;the Huaian Clinical College of Xuzhou Medical University,Huai′an 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院血液科,江苏淮安223300 [2]南京医科大学血液病重点实验室,南京210009 [3]徐州医科大学淮安临床学院,江苏淮安223300

出　　处：《医学综述》2023年第21期4570-4574,4580,共6页Medical Recapitulate

摘　　要：多发性骨髓瘤(MM)是一种克隆浆细胞异常增殖的恶性疾病,发病率呈逐年上升趋势且发病年龄趋于年轻化,但目前尚无法治愈,严重威胁人类生命健康。维奈克拉(Venetoclax)作为抗凋亡蛋白B细胞淋巴瘤/白血病-2(Bcl-2)的一种选择性小分子抑制剂,在血液肿瘤治疗中疗效显著。t(11;14)是MM中最常见的染色体易位,与抗凋亡蛋白Bcl-2具有较强相关性,而Venetoclax单药及联合治疗在伴有t(11;14)的复发/难治性MM(RRMM)患者中疗效显著。因此,未来深入研究Venetoclax在RRMM中的作用机制,可以为疾病的治疗提供新思路。Multiple myeloma(MM)is a malignant hematological disease characterized by clonal proliferation of plasma cells,the incidence of which is increasing year by year and tends to be younger,howeverit is still incurable at present,seriously threatening human life and health.Venetoclax,a selective small-molecule inhibitor of anti-apoptosis protein B cell lymphoma/leukemia-2(Bcl-2),shows significant effect in the treatment of hematologic malignancies.t(11;14)is the most common translocation detected in MM,which is strongly relevant to anti-apoptosis protein Bcl-2.Venetoclax monotherapy and combined therapy show a high curative effect in relapsed/refractory MM(RRMM)patients harboring t(11;14).Therefore,further study of the mechanism of venetoclax in RRMM in the future may provide new ideas for the treatment of the disease.

关 键 词：复发/难治性多发性骨髓瘤 维奈克拉 B细胞淋巴瘤/白血病-2 

分 类 号：R551[医药卫生—血液循环系统疾病]